Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

ADA 23 > 7. Diabetes Technology23 > Flashcards

7. Diabetes Technology23 Flashcards

1
Q

What can CGM be used for in managing hospitalized individuals?

A

CGM can be used in conjunction with BGM to manage hospitalized individuals.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

According to the article, what is the approved method for glucose monitoring in hospitals?

A

Point-of-care BGM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Who should be supported to continue using diabetes devices in an inpatient setting or during outpatient procedures?

A

People with diabetes who are competent to safely use diabetes devices such as insulin pumps and continuous glucose monitoring systems.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What should be established before people with diabetes can continue using diabetes devices in an inpatient setting or during outpatient procedures?

A

Competency and proper supervision.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the purpose of a ‘do-it-yourself’ (DIY) system in diabetes technology?

A

The purpose of a ‘do-it-yourself’ (DIY) system is to combine an insulin pump and a rtCGM with a controller and an algorithm designed to automate insulin delivery.

NOT FDA APPROVED

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What should health care professionals do in regards to systems not approved by the U.S. Food and Drug Administration?

A

Health care professionals should assist in diabetes management to ensure the safety of people with diabetes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are some examples of systems individuals with diabetes may be using that are not approved by the U.S. Food and Drug Administration?

A

Some examples include do-it-yourself closed-loop systems and others.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are some alternative pump options for people with type 2 diabetes?

A

Disposable patch-like devices that provide continuous subcutaneous infusion of rapid-acting insulin with bolus insulin in 2-unit increments or bolus insulin only delivered in 2-unit increments used in conjunction with basal insulin injections.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Do individuals with type 2 diabetes consistently experience reductions in A1C levels when USE PUMP compared with MDI?

A

No, reductions in A1C levels are not consistently seen in individuals with type 2 diabetes when compared with MDI.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What benefits may diabetes technology have in relation to exercise-related hypoglycemia?

A

Diabetes technology may lower the risk of exercise-related hypoglycemia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How can AID systems potentially impact A1C levels?

A

AID systems may reduce A1C levels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is required for currently used hybrid closed-loop systems to calculate prandial doses?

A

The manual entry of carbohydrates consumed is required.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What adjustments must be announced for currently used hybrid closed-loop systems?

A

Adjustments for physical activity must be announced.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What do all AID systems on the market today do?

A

All AID systems on the market today adjust basal delivery in real time and some deliver correction doses automatically.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the three components of Automated Insulin Delivery Systems
AID?

A

The three components are an insulin pump, a continuous glucose monitoring system, and an algorithm for insulin delivery calculation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What do AID systems do to mimic physiologic insulin delivery?

A

AID systems increase and decrease insulin delivery based on sensor-derived glucose levels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What did the (ASPIRE) trial show about sensor-augmented insulin pump therapy with a low glucose suspend function?

A

The (ASPIRE) trial showed that sensor-augmented insulin pump therapy with a low glucose suspend function significantly reduced nocturnal hypoglycemia over 3 months without increasing A1C levels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What type of pumps have been approved by the FDA?

A

Sensor-augmented pumps that suspend insulin when glucose is low or are predicted to go low within the next 30 min.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the purpose of the FDA approval for sensor-augmented pumps?

A

To allow pumps to suspend insulin when glucose is low or are predicted to go low within the next 30 min.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the preferred mode of insulin delivery for children under 7 years of age?

A

According to the content, pump therapy may be the preferred mode of insulin delivery for children under 7 years of age.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

According to the article, what diabetes complications may insulin pump therapy help reduce in youth?

A

Insulin pump therapy may help reduce retinopathy and peripheral neuropathy in youth with diabetes.
may reduce the risk of diabetic ketoacidosis (DKA) and diabetes complications in youth.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the potential benefit of insulin pump therapy mentioned in the article?

A

Insulin pump therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the potential benefit of using insulin pumps?

A

Insulin pumps may reduce the rates of severe hypoglycemia compared with MDI.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What was a major adverse effect of intensified insulin therapy in the Diabetes Control and Complications DCCT Trial?

A

Hypoglycemia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What does the abbreviation RCTs stand for in the given content?

A

RCTs stands for Randomized Controlled Trials.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

According to the article, what improvement is observed in participants on insulin pump therapy compared to MDI with rapid-acting insulin analogs?

A

A modest improvement in A1C is observed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What factor may contribute to better glycemic outcomes for participants on insulin pump therapy?

A

Higher socioeconomic status

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What are some skin issues associated with pump usage?

A

Some skin issues associated with pump usage are lipohypertrophy and lipoatrophy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Do measurement of C-peptide levels or antibodies predict success with insulin pump therapy?

A

There are no data to suggest that measurement of C-peptide levels or antibodies predicts success with insulin pump therapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

When can pump therapy be started?

A

Pump therapy can be successfully started at the time of diagnosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What is the purpose of the PANTHER Program?

A

The PANTHER Program is designed to assist health care professionals and people with diabetes in choosing diabetes devices based on their individual needs and the features of the devices.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What resources can the PANTHER Program and pantherprogram.org provide?

A

The PANTHER Program and pantherprogram.org provide helpful websites to assist health care professionals and people with diabetes in choosing diabetes devices.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What did a systematic review and meta-analysis conclude about pump therapy?

A

Pump therapy has modest advantages for lowering A1C (-0.30% [95% CI -0.58 to -0.02]) and for reducing severe hypoglycemia rates in children and adults.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What are the advantages of pump therapy according to the systematic review and meta-analysis?

A

Pump therapy has modest advantages for lowering A1C (-0.30% [95% CI -0.58 to -0.02]) and for reducing severe hypoglycemia rates in children and adults.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What should individuals with diabetes who have been using continuous subcutaneous insulin infusion have?

A

Individuals with diabetes who have been using continuous subcutaneous insulin infusion should have continued access across third-party payers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What population can insulin pump therapy be offered to for diabetes management?

A

Insulin pump therapy can be offered to youth and adults on multiple daily injections with type 2 diabetes who are capable of using the device safely (either by themselves or with a caregiver).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What factors should be considered when choosing an insulin pump device?

A

The choice of device should be made based on the individual’s circumstances, preferences, and needs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Who should make the decision on which insulin pump device to choose?

A

The individual should make the decision based on their circumstances, preferences, and needs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Who should be offered insulin pump therapy alone or with sensor-augmented pump low glucose suspend feature and/or automated insulin delivery systems for diabetes management?

A

Youth and adults on multiple daily injections with type 1 diabetes A or other types of insulin-deficient diabetes E who are capable of using the device safely (either by themselves or with a caregiver) and are not able to use or do not choose an automated insulin delivery system.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

How should the choice of device be made for insulin pump therapy for diabetes management?

A

The choice of device should be made based on the individual’s circumstances, preferences, and needs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What are the criteria for offering insulin pump therapy alone or with sensor-augmented pump low glucose suspend feature and/or automated insulin delivery systems for diabetes management?

A

The criteria include being on multiple daily injections with type 1 diabetes A or other types of insulin-deficient diabetes E, being capable of using the device safely (either by themselves or with a caregiver), and not being able to use or choosing not to use an automated insulin delivery system.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Who should be offered automated insulin delivery systems for diabetes management?

A

Youth and adults with type 1 diabetes A and other types of insulin-deficient diabetes E who are capable of using the device safely.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What factors should be considered when choosing an automated insulin delivery device?

A

The individual’s circumstances, preferences, and needs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Which group of people should consider using automated insulin delivery systems?

A

Youth and adults with type 1 diabetes A and other types of insulin-deficient diabetes E who are capable of using the device safely.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

What is the potential benefit of using shorter needles during injections?

A

Shorter needles (4–5 mm) may lower the risk of intramuscular injection and possibly the development of lipohypertrophy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

What is the unit increment of U-500 pens?

A

The unit increment of U-500 pens is 5 units.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

In what settings are syringes generally reused?

A

Syringes are generally reused in resource-limited settings.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

What do trials with insulin pens generally show in terms of glycemic outcomes?

A

Trials with insulin pens generally show equivalence or small improvements in glycemic outcomes compared with using a vial and syringe.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

What is the effect of ingesting ascorbic acid (HYDROXYUREA in high doses?

A

Hydroxyurea Dexcom G6, Medtronic Guardian HIGHER SWNSOR READING

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

What is the effect of ingesting ascorbic acid (vitamin C) in high doses?

A

Ingesting ascorbic acid (vitamin C) in high doses can result in higher sensor readings than the actual glucose levels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Which diabetes technology is known to have higher sensor readings than actual glucose levels when hydroxyurea is used?

A

Dexcom G6 and Medtronic Guardian are known to have higher sensor readings than actual glucose levels when hydroxyurea is used.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

What is the biomarker used by the Tetracycline Senseonics Eversense Sensor?

A

The Tetracycline Senseonics Eversense Sensor uses bias within therapeutic concentration ranges.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

What are two diabetes technologies mentioned in the article?

A

The two diabetes technologies mentioned in the article are Hydroxyurea Dexcom G6 and Medtronic Guardian.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Which medication can cause higher sensor readings than actual glucose in the Dexcom G6 system?

A

Acetaminophen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Which substance can cause higher sensor readings than actual glucose in the Medtronic Guardian system?

A

Alcohol

56
Q

Which medication can cause sensor bias within therapeutic concentration ranges in the Senseonics Eversense system?

A

Mannitol

57
Q

How can patch testing help identify the cause of contact dermatitis?

A

Patch testing can sometimes identify the cause of contact dermatitis.

58
Q

Why is it important to identify and eliminate tape allergens?

A

Identifying and eliminating tape allergens is important to ensure the comfortable use of devices and promote self-care.

59
Q

What is one possible solution to avoid skin reactions in individuals sensitive to tape?

A

Using an implanted sensor can help avoid skin reactions in those sensitive to tape.

60
Q

What side effects have been reported with continuous glucose monitoring devices?

A

Contact dermatitis (both irritant and allergic) has been reported with all devices that attach to the skin.

61
Q

What type of devices have been reported to cause contact dermatitis?

A

All devices that attach to the skin have been reported to cause contact dermatitis.

62
Q

What has been reported as a side effect of continuous glucose monitoring devices?

A

Contact dermatitis (both irritant and allergic)

63
Q

What type of devices have reported contact dermatitis as a side effect?

A

Continuous glucose monitoring devices

64
Q

What were the results of the Randomized Control Trials (RCTs) comparing CGM and BGM for people with type 2 diabetes?

A

Both early and late improvements in A1C were found in the RCTs comparing CGM and BGM for people with type 2 diabetes not on intensive insulin therapy.

65
Q

What can professional CGM devices be used for?

A

Professional CGM devices can be used to identify patterns of hypoglycemia and hyperglycemia.

66
Q

What type of data do professional CGM devices provide?

A

Professional CGM devices provide retrospective data, either blinded or unblinded, for analysis.

67
Q

According to the article, what calculation is superior to estimate A1C during pregnancy?

A

The use of rtCGM-reported mean glucose is superior to other calculations to estimate A1C during pregnancy.

68
Q

What is GMI used to estimate?

A

GMI is used to estimate A1C.

69
Q

What is the effect of rtCGM on pregnancy complicated by type 1 diabetes? CONCEPT STUDY

A

rtCGM in pregnancy complicated by type 1 diabetes shows a mild improvement in A1C without an increase in hypoglycemia and reductions in large-for-gestational-age births, length of stay, and neonatal hypoglycemia.

70
Q

What were the benefits of rtCGM over isCGM in adults with T1D?

A

rtCGM was superior to isCGM in reducing hypoglycemia and improving time in range.

71
Q

What did the retrospective study of adults with type 2 diabetes taking insulin ON CGM demonstrate?

A

A reduction in acute diabetes-related events and all-cause hospitalizations was seen.

72
Q

Which diabetes complications have been observed to be reduced when individuals with type 1 diabetes wear isCGM devices?

A

Reductions in acute diabetes complications such as diabetic ketoacidosis (DKA), episodes of severe hypoglycemia or diabetes-related coma, and hospitalizations for hypoglycemia and hyperglycemia have been observed.

73
Q

What is the effect of discontinuing CGM in adults with type 2 diabetes treated with basal insulin?

A

Discontinuing CGM results in a loss of about one-half of the initial gain in TIR that had been achieved during CGM use.

74
Q

How long were adults using real-time CGM before discontinuing it?

A

Adults had been using real-time CGM for 8 months before discontinuing it.

75
Q

According to the article, what improvements have largely occurred in type 2 diabetes using CGM?

A

Improvements in type 2 diabetes have largely occurred without changes in insulin doses or other diabetes medications.

76
Q

What does RCT data on rtCGM use in individuals with type 2 diabetes consistently show?

A

Reductions in A1C but not a reduction in rates of hypoglycemia.

عكس النوع الاول

77
Q

What are the specific populations included in the RCT data on rtCGM use?

A

Individuals with type 2 diabetes on MDI, mixed therapies, and basal insulin.

78
Q

What is the effect of rtCGM in young children with type 1 diabetes?

A

rtCGM in young children with type 1 diabetes reduced hypoglycemia.
LOWER A1C

79
Q

Which continuous glucose monitoring (CGM) system is FDA approved for use with the 670/770G AID systems?

A

The Medtronic Guardian 3 rtCGM is FDA approved for use with the 670/770G AID systems.

80
Q

Which CGM system has iCGM designation and FDA approval for use with AID systems?

A

The Dexcom G6 rtCGM is the only system with iCGM designation and FDA approval for use with AID systems.

81
Q

What is Professional CGM?

A

Professional CGM refers to CGM devices that are placed on the person with diabetes in the health care professional’s office (or with remote instruction) and worn for a discrete period of time (generally 7–14 days). The data collected is used to assess glycemic patterns and trends.

82
Q

What are the different types of CGM systems mentioned in the article?

A

The different types of CGM systems mentioned in the article are rtCGM, isCGM with and without alarms, and Professional CGM.

83
Q

What is the difference between rtCGM and isCGM systems?

A

The main difference between rtCGM and isCGM systems is that rtCGM systems measure and display glucose levels continuously, while isCGM systems measure glucose levels continuously but require scanning for visualization and storage of glucose values.

84
Q

What does CGM measure?

A

CGM measures interstitial glucose.

85
Q

What does interstitial glucose correlate well with?

A

Interstitial glucose correlates well with plasma glucose.

86
Q

Why should skin reactions be assessed and addressed for successful use of devices?

A

Skin reactions should be assessed and addressed to aid in successful use of devices.

87
Q

What should continuous glucose monitoring device users be educated on?

A

Continuous glucose monitoring device users should be educated on potential interfering substances and other factors that may affect accuracy.

88
Q

How can continuous glucose monitoring help achieve A1C targets in diabetes and pregnancy?

A

Continuous glucose monitoring, when used as an adjunct to pre- and postprandial blood glucose monitoring, can help achieve A1C targets in diabetes and pregnancy.

89
Q

In what circumstances can periodic use of real-time or intermittently scanned continuous glucose monitoring be helpful for diabetes management?

A

Periodic use of real-time or intermittently scanned continuous glucose monitoring or use of professional continuous glucose monitoring can be helpful for diabetes management in circumstances where continuous use of continuous glucose monitoring is not appropriate, desired, or available.

90
Q

What are the potential benefits of continuous glucose monitoring in diabetes management?

A

Continuous glucose monitoring can help achieve A1C targets in diabetes and pregnancy when used alongside pre- and postprandial blood glucose monitoring. It can also be helpful in circumstances where continuous use of continuous glucose monitoring is not possible or preferred.

91
Q

What type of diabetes management should be offered for youth with type 2 diabetes on multiple daily injections or continuous subcutaneous insulin infusion?

A

Real-time continuous glucose monitoring or intermittently scanned continuous glucose monitoring should be offered.

92
Q

What factors should be considered when choosing a device for diabetes management?

A

The choice of device should be made based on the individual’s circumstances, preferences, and needs.

93
Q

Who should be capable of using the diabetes management devices safely?

A

Youth with type 2 diabetes on multiple daily injections or continuous subcutaneous insulin infusion who are capable of using the devices safely (either by themselves or with a caregiver) should be able to use the devices.

94
Q

How often should real-time continuous glucose monitoring devices be used in people with diabetes on multiple daily injections or continuous subcutaneous insulin infusion?

A

Real-time continuous glucose monitoring devices should be used as close to daily as possible for maximal benefit.

95
Q

How frequently should intermittently scanned continuous glucose monitoring devices be scanned?

A

Intermittently scanned continuous glucose monitoring devices should be scanned frequently, at a minimum once every 8 h.

96
Q

Why should people with diabetes have uninterrupted access to their supplies for continuous glucose monitoring?

A

People with diabetes should have uninterrupted access to their supplies to minimize gaps in continuous glucose monitoring.

97
Q

What type of glucose monitoring should be offered for diabetes management in youth with type 2 diabetes?

A

Real-time continuous glucose monitoring or intermittently scanned continuous glucose monitoring should be offered.

98
Q

Who should be offered real-time continuous glucose monitoring or intermittently scanned continuous glucose monitoring for diabetes management?

A

Youth with type 2 diabetes on multiple daily injections or continuous subcutaneous insulin infusion who are capable of using the devices safely (either by themselves or with a caregiver).

99
Q

What factors should be considered when choosing a device for glucose monitoring?

A

The choice of device should be made based on the individual’s circumstances, preferences, and needs.

100
Q

What type of continuous glucose monitoring should be offered for diabetes management in youth with type 1 diabetes on multiple daily injections or continuous subcutaneous insulin infusion?

A

Real-time continuous glucose monitoring B or intermittently scanned continuous glucose monitoring E should be offered.

101
Q

What factors should be considered in choosing the device for continuous glucose monitoring in youth with type 1 diabetes?

A

The choice of device should be made based on the individual’s circumstances, preferences, and needs.

102
Q

Who can use the continuous glucose monitoring devices for diabetes management in youth with type 1 diabetes?

A

Youth with type 1 diabetes on multiple daily injections or continuous subcutaneous insulin infusion who are capable of using the devices safely (either by themselves or with a caregiver) can use the devices.

103
Q

What type of continuous glucose monitoring should be offered for diabetes management in adults on basal insulin?

A

Real-time continuous glucose monitoring or intermittently scanned continuous glucose monitoring

104
Q

What factors should be considered when choosing a device for continuous glucose monitoring?

A

The choice of device should be made based on the individual’s circumstances, preferences, and needs.

105
Q

Who should be capable of using continuous glucose monitoring devices safely?

A

Adults with diabetes on basal insulin who are capable of using the devices safely (either by themselves or with a caregiver).

106
Q

What should be offered for diabetes management in adults on multiple daily injections or continuous subcutaneous insulin infusion?

A

Real-time continuous glucose monitoring A or intermittently scanned continuous glucose monitoring B

107
Q

What factors should be considered when choosing a device for diabetes management?

A

The individual’s circumstances, preferences, and needs should be considered.

108
Q

Who should be capable of using the devices safely for diabetes management?

A

Adults with diabetes on multiple daily injections or continuous subcutaneous insulin infusion

109
Q

What are some interfering substances for glucose meter readings with glucose oxidase monitors?

A

Some interfering substances for glucose meter readings with glucose oxidase monitors are uric acid, galactose, xylose, acetaminophen, l-DOPA, and ascorbic acid.

110
Q

What may alter glucose readings on monitors?

A

Humidity and altitude may alter glucose readings.

111
Q

What is the purpose of the temperature range in glucose monitors?

A

The temperature range in glucose monitors is to ensure accurate readings as the reaction is sensitive to temperature.

112
Q

What type of blood should glucose oxidase monitors be used with?

A

Glucose oxidase monitors should only be used with capillary blood.

113
Q

What can result in false low glucose readings with glucose oxidase monitors?

A

Higher oxygen tensions such as arterial blood or oxygen therapy can result in false low glucose readings.

114
Q

What type of blood should glucose dehydrogenase-based monitors be used with?

A

Glucose dehydrogenase-based monitors are not sensitive to oxygen and can be used with any type of blood.

115
Q

What are the two types of enzymatic reactions used in currently available glucose monitors?

A

The two types of enzymatic reactions used are glucose oxidase and glucose dehydrogenase.

116
Q

According to meta-analyses, how much can BGM reduce A1C at 6 months? ON BASAL AND/OR ORAL MEDS?

A

BGM can reduce A1C by 0.25–0.3% at 6 months.

117
Q

How much more did the group using BGM reduce their A1C compared to the control group? ON BASAL AND/OR ORAL MEDS?

A

0.3%

118
Q

WHAT IS THE BENIFIT OF BGM IN T2DM NOT TAKING INSULIN?

A

In people with type 2 diabetes not taking insulin, may be of limited additional clinical benefit

119
Q

What is the evidence regarding when to prescribe BGM and how often monitoring is needed for insulin-treated people with diabetes who do not use intensive insulin therapy?

A

The evidence is insufficient regarding when to prescribe BGM and how often monitoring is needed for insulin-treated people with diabetes who do not use intensive insulin therapy.

EVEN FOR PT ON BASAL + ORAL

120
Q

What is the correlation between greater blood glucose monitoring (BGM) frequency and A1C levels in people with type 1 diabetes?

A

There is a correlation between greater BGM frequency and lower A1C levels in people with type 1 diabetes.

121
Q

What are the recommended accuracy standards for home use blood glucose meters?

A

Home use blood glucose meters should have 95% of readings within 15% accuracy for all blood glucose values in the usable range, and 99% within 20% accuracy.

122
Q

Why must people with diabetes using CGM have access to BGM?

A

People with diabetes using CGM must have access to BGM for multiple reasons, including whenever there is suspicion that the CGM is inaccurate, while waiting for warm-up, for calibration (some sensors) or if a warning message appears, and in any clinical setting where glucose levels are changing rapidly (>2 mg/dL/min), which could cause a discrepancy between CGM and blood glucose.

123
Q

What situations might cause a discrepancy between CGM and blood glucose levels in people with diabetes?

A

Any clinical setting where glucose levels are changing rapidly (>2 mg/dL/min) could cause a discrepancy between CGM and blood glucose levels in people with diabetes.

124
Q

What are some factors that can interfere with glucose meter accuracy?

A

Medications, high-dose vitamin C, and hypoxemia can interfere with glucose meter accuracy.

125
Q

What should health care professionals do in response to factors that can interfere with glucose meter accuracy?

A

Health care professionals should be aware of these factors and provide clinical management as indicated.

126
Q

When can blood glucose monitoring be helpful?

A

Blood glucose monitoring can be helpful when altering nutrition plan, physical activity, and/or medications in conjunction with a treatment adjustment program.

127
Q

What has blood glucose monitoring not consistently shown in individuals on noninsulin therapies?

A

Blood glucose monitoring has not consistently shown clinically significant reductions in A1C in individuals on noninsulin therapies.

128
Q

When should people on insulin using blood glucose monitoring check their blood glucose levels?

A

People on insulin using blood glucose monitoring should be encouraged to check their blood glucose levels when appropriate based on their insulin therapy. This may include checking when fasting, prior to meals and snacks, after meals, at bedtime, prior to exercise, when hypoglycemia is suspected, after treating low blood glucose levels until they are normoglycemic, when hyperglycemia is suspected, and prior to and while performing critical tasks such as driving.

129
Q

What are some situations when people on insulin using blood glucose monitoring should check their blood glucose levels?

A

People on insulin using blood glucose monitoring should check their blood glucose levels when fasting, prior to meals and snacks, after meals, at bedtime, prior to exercise, when hypoglycemia is suspected, after treating low blood glucose levels until they are normoglycemic, when hyperglycemia is suspected, and prior to and while performing critical tasks such as driving.

130
Q

Why should people on insulin using blood glucose monitoring check their blood glucose levels in specific situations?

A

People on insulin using blood glucose monitoring should check their blood glucose levels in specific situations to monitor the effectiveness of their insulin therapy, ensure they are maintaining target blood glucose levels, and take appropriate actions such as adjusting insulin dosage or treating hypoglycemia or hyperglycemia.

131
Q

What are the benefits of early CGM initiation after diagnosis of type 1 diabetes in youth?

A

Early CGM initiation after diagnosis of type 1 diabetes in youth has been shown to decrease A1C and is associated with high parental satisfaction and reliance on this technology for diabetes management.

132
Q

When should the use of CGM devices be considered?

A

The use of CGM devices should be considered from the outset of the diagnosis of diabetes that requires insulin management.

133
Q

According to the Diabetes Technology Standards of Care, how should the selection of devices be determined?

A

The type(s) and selection of devices should be individualized based on a person’s specific needs, preferences, and skill level.

134
Q

What should be ensured when prescribing a device for people with diabetes or caregivers?

A

Ensure that people with diabetes/caregivers receive initial and ongoing education and training, either in-person or remotely, and ongoing evaluation of technique, results, and their ability to utilize data, including uploading/sharing data (if applicable), to monitor and adjust therapy.

135
Q

According to the Diabetes Technology Standards of Care, who should have continued access to continuous glucose monitoring, continuous subcutaneous insulin infusion, and/or automated insulin delivery for diabetes management?

A

People with diabetes who have been using continuous glucose monitoring, continuous subcutaneous insulin infusion, and/or automated insulin delivery for diabetes management should have continued access across third-party payers, regardless of age or A1C levels.

136
Q

How should students with diabetes be supported at school in terms of diabetes technology?

A

Students should be supported at school in the use of diabetes technology, such as continuous glucose monitoring systems, continuous subcutaneous insulin infusion, connected insulin pens, and automated insulin delivery systems, as prescribed by their health care team.

137
Q

What does the term ‘diabetes technology’ encompass?

A

Diabetes technology encompasses the hardware, devices, and software used by people with diabetes for self-management, including lifestyle modifications, glucose monitoring, and therapy adjustments.

ADA 23 (9 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions